Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Zscaler Inc (ZS) Price & Performance

Amphastar Pharmaceuticals IncTrade
Zscaler IncTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Zscaler Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.87 (market cap $868.62M), while Zscaler Inc trades at $177.1 (market cap $28.87B). The key difference: Zscaler Inc is far larger — about 33.2× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

AMPHZS
Market Cap
$868.62M$28.87B
Sector
HealthTechnology
52-Week High
$30.81$336.27
52-Week Low
$16.87$118.05
Enterprise Value
$1.27B$27.20B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.

The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.

Zscaler Inc

Zscaler (ZS) trades at $176.68, up 4.74% with strong technical momentum and bullish analyst sentiment. The stock shows consistent revenue growth from $1.1B in 2022 to $2.67B in 2025, though profitability remains negative with a -2.44% net margin. Recent earnings beats and leadership in Gartner's Magic Quadrant for security platforms support positive momentum, while elevated valuation ratios (P/S 8.94, EV/EBITDA 188.83) reflect growth expectations.

Outlook remains cautiously optimistic with 79% analyst buy ratings and $191.81 consensus target, but risks include persistent unprofitability, high spending, and competitive pressures. The upcoming Q2 2026 earnings report on September 3 will be critical for validating growth trajectory amid concerns about execution and valuation sustainability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Zscaler Inc

Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.

Read more on ZS